Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.53 |
| ▸ | CTSS | P25774 | 7/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 9/20 | 0.50 |
| ▸ | TACR2 | P21452 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16375232 | 0.88 | L3MBTL1 (0.59) | L3MBTL1KMT2AGRIA1CTSSCTSK | |
| SCHEMBL16375201 | 0.88 | CTSL (0.53) | L3MBTL1KMT2AGRIA1CTSSCTSK | |
| SCHEMBL16375212 | 0.83 | PTPN1 (0.57) | — | |
| SCHEMBL16375200 | 0.81 | MME (0.53) | L3MBTL1CTSSCTSKCTSBCTSL | |
| SCHEMBL17994241 | 0.80 | L3MBTL1 (0.57) | L3MBTL1KMT2AGRIA1CTSSCTSK | |
| SCHEMBL16375204 | 0.79 | CTSS (0.50) | L3MBTL1CTSSCTSKCTSBCTSL | |
| SCHEMBL16306220 | 0.79 | GCGR (0.56) | L3MBTL1CTSSCTSKCTSBCTSL | |
| SCHEMBL16375233 | 0.77 | CTSL (0.54) | L3MBTL1KMT2ACTSSCTSKCTSB | |
| SCHEMBL15037188 | 0.77 | MME (0.53) | L3MBTL1CTSSCTSKCTSB | |
| SCHEMBL22448948 | 0.77 | MME (0.53) | L3MBTL1CTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | L3MBTL1 771/4885KMT2A 4232/4885GRIA1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.